<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Euthymics Bioscience, Inc.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        72433589
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       162689
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       3
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Euthymics Bioscience wants to put patients in a pleasant state of mind. Named for a medical term defined as a moderate mood that's neither manic nor depressed, Euthymics Bioscience is a biopharmaceutical company focused on developing drugs that treat major depression and ADHD. The company's lead candidate, amitifadine, is a clinical-stage, orally administered treatment for depression that acts on the neurotransmitters serotonin, norepinephrine, and dopamine. Its other key candidate, also in clinical-stage development, is being developed to treat ADHD in adults. Founded in 2009, Euthymics Bioscience has received financial backing from Novartis Venture Fund, Venture Investors, GBS Partners, and other investors.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
